• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Lisdexamfetamine for BED: How Effective Over the Long Term?

Lisdexamfetamine for BED: How Effective Over the Long Term?

April 1, 2018
Robert T. Rubin, MD, PhD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Robert T. Rubin, MD, PhD. Dr. Rubin has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Hudson JI et al, JAMA Psychiatry 2017;74(9):903–910.

Lisdexamfetamine (Vyvanse) is an extended release amphetamine-based stimulant that is approved for both ADHD and binge eating disorder (BED). To refresh your memory, BED is defined as recurrent episodes (at least once a week over 3 months) of binge eating without compensatory weight loss behaviors, such as purging or excessive exercise. Vyvanse was approved for BED in 2015, and it’s currently the only medication approved for this indication. The approval was based on the results of two 12-week randomized controlled trials, in which the stimulant (at doses of 50–70 mg/day) was more effective than placebo at reducing binge frequency. (See TCPR June 2015 for more details.)

This study, funded by Shire, Vyvanse’s manufacturer, was designed to test Vyvanse’s efficacy over the long term for patients with more severe BED. The study included 411 patients from 49 centers in North America and Europe who were binging at least 3 times per week. They were initially treated for 12 weeks with Vyvanse (50–70 mg per day) in an open-label study, and 270 of these patients responded, as defined by no more than 1 binge per week for 4 consecutive weeks. The responders then were randomized, in double-blind fashion, to continued Vyvanse at the same dose, or to placebo for another 6 months.

Patients assigned to continue Vyvanse did markedly better—only 3.7% of these patients relapsed vs 32% of the patients switched to placebo. Among the 32% of placebo-treated patients, half of them relapsed within the first month. Side effects in both groups were mild; there were modest increases in blood pressure and pulse in the Vyvanse group, as well as some weight loss.

TCPR’s Take
This study shows that Vyvanse is effective for BED over the long term, but patients who are reluctant to take a stimulant for BED can be reassured that once they get better, they most likely can taper off the Vyvanse without relapsing. It would be nice if we could predict which patients can successfully be weaned from Vyvanse, but this study didn’t examine that issue. Based on this study, you can tell your BED patients that—if they come off the stimulant—they have about a 66% chance of maintaining their response.
General Psychiatry
KEYWORDS eating_disorders research_updates
    Robert T. Rubin, MD, PhD.

    More from this author
    www.thecarlatreport.com
    Issue Date: April 1, 2018
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Neurofeedback, TCPR, April 2018
    Neurofeedback in Psychiatry: What’s the Evidence?
    An Antidepressant Diet
    Lisdexamfetamine for BED: How Effective Over the Long Term?
    Is There a Connection Between Hormonal Contraception and Suicide?
    Is EEG Useful in Psychiatry?
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.